drugset / Trial / NCT04897477
Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, single arm, phase I/II for patients with r/r Non-Hodgkin's Lymphoma . The purpose is to evaluate the safety and efficacy of the combination with Azacytidine, Bendamustine and Piamprizumab
Timeline
- Start
- 2021-04-22
- Primary completion
- 2022-04-23
- Completion
- 2023-04-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | Subcutaneous |
| Subject | Bendamustine | Small molecule | — | Intravenous |
| Subject | Piamprizumab | Unknown | — | Intravenous |